Larger Dosage Required for Everolimus than Sirolimus to Maintain Same Blood Concentration in Two Pancreatic Islet Transplant Patients with Tacrolimus
- 1 January 2009
- journal article
- case report
- Published by Japanese Society for the Study of Xenobiotics in Drug Metabolism and Pharmacokinetics
- Vol. 24 (2) , 175-179
Abstract
We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients. Both patients were administered tacrolimus with sirolimus or everolimus. They had been administered 5 or 9 mg sirolimus once a day and had maintained a trough concentration of about 15 ng/mL as measured by high performance liquid chromatography with ultraviolet detection. After the switch from sirolimus to everolimus, they were given 10 or 12 mg/day of everolimus twice a day to maintain a trough concentration of 12-15 ng/mL as measured by a fluorescence polarization immunoassay (FPIA) method. Afterward, the blood concentrations of everolimus and sirolimus after the conversion were measured by high performance liquid chromatography with mass spectrometry and everolimus concentrations were found to be 5-10 ng/mL. These data show that a larger dosage is needed for everolimus than sirolimus to maintain the same trough blood concentration. Data obtained by the FPIA for everolimus should be carefully evaluated after switching from sirolimus to everolimus because of the cross-reactivity of the antibody with sirolimus.Keywords
This publication has 20 references indexed in Scilit:
- Temporal Decline in Sirolimus Elimination Immediately After Pancreatic Islet TransplantationDrug Metabolism and Pharmacokinetics, 2006
- Insulin independence after living-donor distal pancreatectomy and islet allotransplantationThe Lancet, 2005
- Influence of Delayed Initiation of Cyclosporine on Everolimus Pharmacokinetics in de Novo Renal Transplant PatientsAmerican Journal of Transplantation, 2003
- Pharmacokinetic Interactions between Sirolimus and Microemulsion Cyclosporine When Orally Administered Jointly and 4 Hours Apart in Healthy VolunteersThe Journal of Clinical Pharmacology, 2003
- Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney TransplantationAmerican Journal of Transplantation, 2003
- mTOR inhibitors: An overviewLiver Transplantation, 2001
- Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RADTransplantation Proceedings, 2001
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000
- In Vitro and In Situ Absorption of SDZ-RAD Using a Human Intestinal Cell Line (Caco-2) and a Single Pass Perfusion Model in Rats: Comparison with RapamycinPharmaceutical Research, 1998
- Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug deliveryAdvanced Drug Delivery Reviews, 1997